Highlights Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
16.17 ^USD	+0.87%		-1.28%	+10.75%

May. 07	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	MT
May. 06	Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma	Apr. 23	CI
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment	Apr. 23	MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Day One Biopharmaceuticals, Inc. Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma	23-10-30	CI
Day One Completes Rolling Submission of New Drug Application for Pediatric Brain Tumor Drug	23-09-11	MT
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling Nda Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma	23-09-11	CI
Day One Biopharmaceuticals, Sprint Bioscience Sign Exclusive License, Research Deal	23-08-16	MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Day One Biopharmaceuticals Announces New FireFLY-1 Data for Tovorafenib and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma	23-06-04	CI
DAY ONE BIOPHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-01	AQ
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-01	CI
Day One Biopharmaceuticals Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology Annual Meeting	23-04-26	CI
Day One Biopharmaceuticals' Q4 Loss Widens	23-03-07	MT
DAY ONE BIOPHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-06	AQ
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Day One Biopharmaceuticals, Inc. Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib in Recurrent or Progressive Pediatric Low-Grade Glioma	23-01-08	CI
Day One Biopharmaceuticals Q3 Loss Widens	22-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Highlights

Filters